About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a company based in United States founded in 1989 by Joshua Boger. The company has 6,100 employees as of December 31, 2024. Vertex Pharmaceuticals has completed 5 acquisitions, including Alpine Immune Sciences, Crinetics and Exonics. Vertex Pharmaceuticals offers products and services including Cystic Fibrosis Medicines, Kidney Disease Treatments, and Clinical Trial Programs. Vertex Pharmaceuticals operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter United States
- Employees 6100 as on 31 Dec, 2024
- Founders Joshua Boger
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vertex Pharmaceuticals Incorporated
-
Annual Revenue
$12.07 B (USD)9.92as on Dec 31, 2025
-
Net Profit
$3.95 B (USD)0as on Dec 31, 2025
-
EBITDA
$4.97 B (USD)8.82as on Dec 31, 2025
-
Latest Funding Round
$350 K (USD), Grant
Feb 02, 2010
-
Investors
HHS
& 1 more
-
Employee Count
6100
as on Dec 31, 2024
-
Investments & Acquisitions
Alpine Immune Sciences
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vertex Pharmaceuticals
Vertex Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol VRTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vertex Pharmaceuticals
Vertex Pharmaceuticals offers a comprehensive portfolio of products and services, including Cystic Fibrosis Medicines, Kidney Disease Treatments, and Clinical Trial Programs.
Treatments targeting cystic fibrosis symptoms and progression
Medicines for APOL1-mediated kidney diseases
Platforms for testing new medicines in trials
People of Vertex Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
249 people
Software Development Team
218 people
Senior Team
136 people
Principal Team
61 people
Finance and Accounting
53 people
Operations Team
35 people
Legal and Compliance
34 people
Sales and Marketing
30 people
Unlock access to complete
Funding Insights of Vertex Pharmaceuticals
Investors in Vertex Pharmaceuticals
Vertex Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Vertex Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vertex Pharmaceuticals
Vertex Pharmaceuticals has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Alpine Immune Sciences, Crinetics and Exonics.
Investment portfolio details for Vertex Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRISPR/Cas-9 therapies for Duchenne Muscular Dystrophy are developed.
|
Locked | Locked | 2016 | Locked | |
|
Developer of immunotherapies to treat cancer and autoimmune disorders
|
Locked | Locked | 2015 | Locked | |
|
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Vertex Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Vertex Pharmaceuticals
Detailed financials for Vertex Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vertex Pharmaceuticals Comparisons
Peer comparison for Vertex Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vertex Pharmaceuticals
Vertex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Detailed competitors of Vertex Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vertex Pharmaceuticals
Complete news archive for Vertex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vertex Pharmaceuticals
Vertex Pharmaceuticals was founded in 1989 and raised its 1st funding round 5 years after it was founded.
Vertex Pharmaceuticals is headquartered in United States.
Reshma Kewalramani is the current CEO of Vertex Pharmaceuticals.
As of Dec 31, 2024, the latest employee count at Vertex Pharmaceuticals is 6,100.
Annual revenue of Vertex Pharmaceuticals is $12.07B as on Dec 31, 2025.
Vertex Pharmaceuticals was founded in 1989 in the United States. Operations focus on the biotechnology sector, where small molecule drugs are developed to address cystic fibrosis, viral diseases, inflammation, autoimmune conditions, cancer, and pain. Treatments such as IVACAFTOR and LUMACAFTORIVACAFTOR target the CFTR protein by enhancing channel opening and preventing misfolding. In 2022, annual revenues reached 8.93 billion, with net profit at 3.32 billion.
Vertex Pharmaceuticals's top competitors include Merck, Roivant Sciences and AbbVie.
Vertex Pharmaceuticals offers Cystic Fibrosis Medicines, Kidney Disease Treatments, and Clinical Trial Programs.
Yes, Vertex Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol VRTX.
Vertex Pharmaceuticals has made 5 acquisitions, including Alpine Immune Sciences, Crinetics, and Exonics.
Vertex Pharmaceuticals has 2 investors. Key investors include HHS, and Athyrium Capital Management.
The ticker symbol of Vertex Pharmaceuticals is VRTX on NASDAQ.